Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 14

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 14
---
 analysts ceases coverage of us or fails to publish reports on us regularly, demand for our Class A ordinary shares
could decrease and we could lose visibility in the financial markets, which could cause the price and trading volume of our ordinary shares
to decline.

<div align='center'>S-7

CAPITALIZATION</div>

The following table sets forth our capitalization
as of June 30, 2024:

| ● | on an actual basis, as derived from our unaudited consolidated financial statements as of June 30,                                       
 2024, which are incorporated by reference into this prospectus supplement; and                                                           |
|:--|:-----------------------------------------------------------------------------------------------------------------------------------------|
| ● | on an adjusted basis to give further effect to the issuance                                                                              
 and sale of 1,535,000 Class A ordinary shares at the offering price of US$2.00 per Class A ordinary share, after deducting the estimated 
 offering expenses payable by us.                                                                                                         |

You should read this table together with our consolidated
financial statements and notes included in the information incorporated by reference into this prospectus supplement and the accompanying
prospectus.

<div align='center'>As of June 30, 2024

(All amounts in USD, except for share and per share data, unless otherwise noted)</div>

|                                                                                                                                                                                                                                                                |     | Actual |             |   |     | Pro      
 forma As 
 Adjusted |             |   |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|------------:|:--|:----|:---------|------------:|:--|
| Cash and cash equivalents                                                                                                                                                                                                                                      |     | $      |     783,085 |   |     |          |   3,482,285 |   |
| Short-term debts, including amount due to a related party                                                                                                                                                                                                      |     |        |      79,180 |   |     |          |      79,180 |   |
| Long-term debt                                                                                                                                                                                                                                                 |     |        |           - |   |     |          |           - |   |
| Convertible notes and interest payable                                                                                                                                                                                                                         |     |        |   3,148,500 |   |     |          |   3,148,500 |   |
| Total indebtedness                                                                                                                                                                                                                                             |     | $      |   3,227,680 |   |     |          |   3,227,680 |   |
| Shareholders’ equity: